Melanoma Death Rate Among Men Increasing



More men are dying from melanoma compared with women, according to a recent study.

Findings from the study, which highlighted trends in global melanoma deaths, were presented at the 2018 National Cancer Research Institute Cancer Conference in Glasgow, UK.  
AAD Releases New Melanoma Management Guidelines
Melanoma Brain Metastases Effectively treated with Combo Therapy
Does Sunscreen Impact Melanoma Risk?
In the study, the researchers used the World Health Organization’s mortality database to identify deaths from melanoma. A total of 33 countries with reliable data were included in the final analysis, and age-standardized death rates were calculated.

The 3-year average age-standardized death rates for 2013 through 2015 were highest in Australia (5.72 per 100,000 in men and 2.53 per 100,000 in women) and Slovenia (3.86 per 100,000 in men and 2.58 per 100,000 in women), but lowest in Japan (0.24 per 100,000 in men and 0.18 per 100,000 in women).

Overall, the melanoma mortality rate was greater among men compared with women. All countries showed increased melanoma mortality rates among men, aside from the Czech Republic, which showed a single decreasing trend in mortality. Conversely, the majority of countries showed decreases or stabilizing trends in melanoma mortality among women. The greatest decreases were observed in Israel (-23.4%) and the Czech Republic (-15.5%).

“There is a persisting global sex disparity in melanoma mortality over the past 30 years. In some regions, this is due either to greater increases in mortality rates in males compared to females, or to decreasing or stabilizing mortality trends in females not paralleled in males,” the researchers concluded. “Future work will explore potential explanatory factors for the observed trends and sex disparity in melanoma mortality.”


Yang D, Salciccioli J, Marshall D, Shalhoub J. Trends in mortality from malignant melanoma: an observational study of the World Health Organisation mortality database from 1985 to 2015. Presented at: 2018 National Cancer Research Institute Cancer Conference; November 4-6, 2018; Glasgow, UK.